未知生产厂商
Ociperlimab (BGB-A1217) is an anti-TIGIT monoclonal antibody currently in phase III clinical trials for solid tumors. It is being developed as a second-generation immune checkpoint inhibitor, with clinical data demonstrating promising profiles in solid tumors when used in combination with PD-1 inhibitors.
Ociperlimab (BGB-A1217) is an anti-TIGIT monoclonal antibody currently in phase III clinical trials for solid tumors. It is being developed as a second-generation immune checkpoint inhibitor, with clinical data demonstrating promising profiles in solid tumors when used in combination with PD-1 inhibitors.
Ociperlimab is an anti-TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) monoclonal antibody. TIGIT exerts immunosuppressive effects primarily through competitive engagement with ligands CD155 and CD112, interrupting the activating signals mediated by CD226, a co-stimulatory receptor for T and NK cell cytotoxic activity. By blocking TIGIT, ociperlimab prevents this immunosuppressive signaling, thereby enhancing anti-tumor immunity. TIGIT blockade has demonstrated the capacity to reverse T-cell exhaustion and mitigate NK cell depletion, particularly when combined with PD-1 inhibition.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
